Juxtapid lomitapide regulatory update

Aegerion said Health Canada approved Juxtapid lomitapide as an adjunct to a low-fat diet and other lipid-lowering therapies, with or without LDL apheresis, to reduce LDL-C in adults with homozygous fa...